Pharma manufacturer Kincell Bio secures US$36m in funding
04 Aug 2023
Cell TherapyImmunotherapy
Preview
Source: Healthcare Digital
Clinical development of cell therapies
Kincell Bio to develop cell therapy with US$36m funding, in a round led by Kineticos Ventures, to bring life-saving treatments to patients
Pharmaceutical manufacturer Kincell Bio has received US$36m in stealth funding, which was led by Kineticos Ventures.
Pharmaceutical manufacturing development
Kincell Bio engineers cells into therapies and manufactures commercially viable immune cell therapies, including autologous and allogeneic CAR-T, CAR-NK and CAR-M programmes. Kincell provides analytical development, CMC consulting and early-stage GMP manufacturing focusing on immune cell therapies.
Kineticos Ventures has investments including biotechs and life science services who want to transform drug development. The company funds research into oncology, neurosciences and rare diseases.
Kincell now has a facility at its Gainesville site, with an ambition to grow bigger.
The clinical development of cell therapies
Shailesh Maingi, founder of Kineticos Ventures, will be the Chair of the Kincell Board of Directors.
“Kincell represents a significant step forward in bridging the gap between laboratory research and clinical development of cell therapies. By addressing the manufacturing challenges faced by early-stage innovators, Kincell is playing a vital role in accelerating the progress of cell therapy innovation. We are excited to support their mission to make cell therapy manufacturing more accessible and streamlined, ultimately bringing life-changing treatments to patients in need.”
Bruce Thompson, the CEO of Kincell, will also serve on the Board of Directors.
“Kincell is at the forefront of innovative cell therapy manufacturing, and I am honoured to lead this exceptional team. Our mission is to enable early-stage biotech companies to bring their life-changing therapies to patients by providing accessible and high-quality manufacturing services,” said Thompson. “With our technology-forward approach and focus on immune cell therapies, we are poised to accelerate the advancement of cell therapies from bench to bedside. I am excited about the potential impact we can make in the field and look forward to collaborating with our partners to drive innovation and improve patients' lives.”
Although Kincell didn’t quite make the list, you can read our Top 10 Pharmaceutical Manufacturers here - including Pfizer, Novartis, Sanofi, GSK, Merck, Roche, AbbVie, Bristol Myers Squibb and Central Pharma.
*********************************************
For more insights into Healthcare - check out the latest edition of Healthcare Digital and be sure to follow us on LinkedIn & Twitter.
Other magazines that may be of interest - Manufacturing Magazine.
*********************************************
BizClik is a global provider of B2B digital media platforms that cover 'Executive Communities' for CEO's, CFO's, CMO's, Sustainability Leaders, Procurement & Supply Chain Leaders, Technology & AI Leaders, Cyber Leaders, FinTech & InsurTech Leaders as well as covering industries such as Manufacturing, Mining, Energy, EV, Construction, Healthcare + Food & Drink.
BizClik, based in London, Dubai & New York offers services such as Content Creation, Advertising & Sponsorship Solutions, Webinars & Events.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.